Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies.

MLA

Rodriguez, Ismael, et al. “Structural and Biological Characterization of PAC65, a Macrocyclic Peptide That Blocks PD-L1 with Equivalent Potency to the FDA-Approved Antibodies.” Molecular Cancer, vol. 22, no. 1, Sept. 2023, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12943-023-01853-4.

APA

Rodriguez, I., Kocik-Krol, J., Skalniak, L., Musielak, B., Wisniewska, A., Ciesiołkiewicz, A., Berlicki, Ł., Plewka, J., Grudnik, P., Stec, M., Siedlar, M., Holak, T. A., & Magiera-Mularz, K. (2023). Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies. Molecular Cancer, 22(1), 1–8. https://doi.org/10.1186/s12943-023-01853-4

Chicago

Rodriguez, Ismael, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, et al. 2023. “Structural and Biological Characterization of PAC65, a Macrocyclic Peptide That Blocks PD-L1 with Equivalent Potency to the FDA-Approved Antibodies.” Molecular Cancer 22 (1): 1–8. doi:10.1186/s12943-023-01853-4.